Bladder Cancer Pipeline constitutes 80+ key companies continuously working towards developing 100+ Bladder Cancer treatment therapies, analyzes DelveInsight.
Bladder Cancer Overview:
Bladder cancer usually starts in the cells that line the inside of the bladder and occurs more frequently in men, especially those over the age of 70. It ranks as the fifth most common cancer overall and the fourth most common among men. While early-stage bladder cancer often responds well to treatment, there’s a risk of recurrence even after several years, making regular follow-up essential. Around 90% of cases are urothelial carcinomas, which are typically non-muscle invasive. Rarer types, such as squamous cell carcinoma, adenocarcinoma, and small cell carcinoma, often result from chronic bladder irritation and have a higher chance of invading the bladder muscle.
The primary symptom is blood in the urine, though other signs can include painful or burning urination, increased frequency, or difficulty urinating. In more advanced stages, patients may experience lower back pain, fatigue, appetite loss, and weight loss. Smoking is the most significant risk factor, with smokers being up to four times more likely to develop bladder cancer. In fact, tobacco use is linked to roughly half of all bladder cancer cases.
Request for a detailed insights report on Bladder Cancer pipeline insights
“Bladder Cancer Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Bladder Cancer Therapeutics Market.
Key Takeaways from the Bladder Cancer Pipeline Report
DelveInsight’s Bladder Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Bladder Cancer treatment.
In February 2025, CG Oncology began the Phase III PIVOT-006 clinical trial of cretostimogene for treating intermediate-risk non-muscle invasive bladder cancer (NMIBC), with the first patient receiving treatment.
In February 2025, ImmunityBio announced that Patient-Reported Outcomes (PROs) from the Phase II/III QUILT 3.032 study of N-803 plus BCG in BCG-unresponsive NMIBC were published in the peer-reviewed journal *Urology Practice*. These PROs supported the positive interim results from the study, published in NEJM Evidence, showing that 71% of patients in cohort A with carcinoma in situ (CIS) with or without Ta/T1 disease achieved a complete response.
In February 2025, UK-based Prokarium initiated the PARADIGM-1 Phase I/Ib study in the US, dosing the first patient with ZH9, an investigational bacterial immunotherapy for NMIBC.
In January 2025, the FDA granted fast track and breakthrough therapy designations to cretostimogene grenadenorepvec (CG0070) for use in patients with high-risk, BCG-unresponsive NMIBC with carcinoma in situ, with or without Ta or T1 tumors.
In January 2025, Canadian pharmaceutical company Theralase Technologies released interim clinical data from its Phase II study of Ruvidar (TLD-1433), an intravesical photodynamic therapy for treating NMIBC.
Key Bladder Cancer companies such as UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co.Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc, enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, CG Oncology, Inc., Astellas Pharma Global Development, Inc, Five Prime Therapeutics, Inc., and others are evaluating new drugs for Bladder Cancer to improve the treatment landscape.
Promising Bladder Cancer pipeline therapies in various stages of development include UGN-102, APL 1202, Trilaciclib, Catumaxomab, VAX 014, and others.
Bladder Cancer Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Bladder Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bladder Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Bladder Cancer market.
Download our free sample page report on Bladder Cancer pipeline insights
Bladder Cancer Emerging Drugs
UGN-102: UroGen Pharma Ltd.
APL 1202 : Asieris Pharmaceuticals
Trilaciclib: G1 Therapeutics, Inc.
Catumaxomab: LintonPharm Co.,Ltd.
VAX 014: Vaxiion Therapeutics
Bladder Cancer Companies
Over 80 key companies are working on developing therapies for bladder cancer. Among them, UroGen Pharma Ltd. has drug candidates for bladder cancer in the most advanced stage, Phase III.
DelveInsight’s report covers around 100+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Bladder Cancer Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Bladder Cancer Therapies and Key Companies: Bladder Cancer Clinical Trials and advancements
Bladder Cancer Pipeline Therapeutic Assessment
• Bladder Cancer Assessment by Product Type
• Bladder Cancer By Stage
• Bladder Cancer Assessment by Route of Administration
• Bladder Cancer Assessment by Molecule Type
Download Bladder Cancer Sample report to know in detail about the Bladder Cancer treatment market @ Bladder Cancer Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Bladder Cancer Current Treatment Patterns
4. Bladder Cancer – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Bladder Cancer Late-Stage Products (Phase-III)
7. Bladder Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Bladder Cancer Discontinued Products
13. Bladder Cancer Product Profiles
14. Bladder Cancer Key Companies
15. Bladder Cancer Key Products
16. Dormant and Discontinued Products
17. Bladder Cancer Unmet Needs
18. Bladder Cancer Future Perspectives
19. Bladder Cancer Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Bladder Cancer Pipeline Reports Offerings
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
